1. Home
  2. PCVX vs BIO Comparison

PCVX vs BIO Comparison

Compare PCVX & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCVX
  • BIO
  • Stock Information
  • Founded
  • PCVX 2013
  • BIO 1952
  • Country
  • PCVX United States
  • BIO United States
  • Employees
  • PCVX N/A
  • BIO N/A
  • Industry
  • PCVX Biotechnology: Pharmaceutical Preparations
  • BIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • PCVX Health Care
  • BIO Industrials
  • Exchange
  • PCVX Nasdaq
  • BIO Nasdaq
  • Market Cap
  • PCVX 4.4B
  • BIO 6.0B
  • IPO Year
  • PCVX 2020
  • BIO N/A
  • Fundamental
  • Price
  • PCVX $34.50
  • BIO $250.73
  • Analyst Decision
  • PCVX Strong Buy
  • BIO Strong Buy
  • Analyst Count
  • PCVX 10
  • BIO 4
  • Target Price
  • PCVX $136.50
  • BIO $324.25
  • AVG Volume (30 Days)
  • PCVX 1.5M
  • BIO 397.8K
  • Earning Date
  • PCVX 08-05-2025
  • BIO 07-31-2025
  • Dividend Yield
  • PCVX N/A
  • BIO N/A
  • EPS Growth
  • PCVX N/A
  • BIO N/A
  • EPS
  • PCVX N/A
  • BIO N/A
  • Revenue
  • PCVX N/A
  • BIO $2,541,100,000.00
  • Revenue This Year
  • PCVX N/A
  • BIO N/A
  • Revenue Next Year
  • PCVX N/A
  • BIO $3.49
  • P/E Ratio
  • PCVX N/A
  • BIO N/A
  • Revenue Growth
  • PCVX N/A
  • BIO N/A
  • 52 Week Low
  • PCVX $27.66
  • BIO $211.43
  • 52 Week High
  • PCVX $121.06
  • BIO $387.99
  • Technical
  • Relative Strength Index (RSI)
  • PCVX 53.91
  • BIO 62.71
  • Support Level
  • PCVX $31.79
  • BIO $245.87
  • Resistance Level
  • PCVX $34.63
  • BIO $255.13
  • Average True Range (ATR)
  • PCVX 1.38
  • BIO 6.95
  • MACD
  • PCVX 0.09
  • BIO 1.56
  • Stochastic Oscillator
  • PCVX 86.31
  • BIO 83.54

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: